1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Invitae Corporation

Invitae Corporation

NVTAQ
Invitae CorporationUS flagOther OTC
0.00
USD
+0.00
- -
85,948.00Market Cap
Invitae Corporation
NVTAQ
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
- -
0.01
0.05
0.3
0.75
1.47
2.21
2.39
2.08
2.18
2.19
1.86
Revenue per Share
-0.61
-1.68
-1.59
-3.18
-3.02
-2.65
-1.94
-2.66
-4.47
-1.8
-13.18
-5.58
Basic EPS, GAAP
-0.67
-1.85
-1.65
-3.09
-2.65
-2.25
-1.47
-1.82
-2.39
-2.91
-2.32
-0.96
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.86
-2.53
-2.86
-6.2
-8.3
-8.57
-7.74
-8.35
-10.11
-8.17
-20.49
-23.88
Book Value per Share
-0.86
-2.51
-2.8
4.9
2.99
0.85
1.22
1.41
-6.46
-2.34
-3.86
-4.19
Tangible Book Value per Share
15
15
30
28
33
47
67
91
135
211
236
258
Basic Weighted Avg Shares
- -
- -
2
8
25
68
148
217
280
460
516
482
Sales/Revenue/Turnover
- -
-16,725
-2,952.12
-1,068
-399.96
-177.77
-82.98
-112.54
-213.75
-169.03
-138.34
-104.48
Operating Margin (%)
- -
1
2
5
7
9
14
16
39
80
142
138
Depreciation Expense
-9
-25
-47
-90
-100
-123
-129
-242
-602
-379
-3,106
-1,441
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-16,782.43
-2,960.85
-1,071.64
-400.26
-180.85
-87.58
-111.6
-215.37
-82.31
-601.64
-299.14
Profit Margin (%)
21
42
102
120
87
53
129
361
332
1,035
585
220
Working Capital
1
1
2
7
9
42
76
312
440
1,708
1,731
1,460
LT Debt
-13
-37
-84
138
99
122
162
380
1,976
2,978
102
-1,083
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
93
21
49
LT Borrowings
1,380
1,420
1,324
LT Finance Leases
146
141
136
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
261
267
286
Market Capitalization
325
281
156

Working Capital

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
504
451
378
Cash, Cash Equivalents & STI
379
325
255
Accounts Receivable, Net
86
86
83
Inventories
19
21
22
Total Current Liabilities
190
152
158
Payables & Accruals
54
85
66
ST Debt
93
21
49
Deferred Revenue
6
5
5

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
58.75%
108.43%
-96.58%
Free Cash Flow
59.01%
47.35%
-11.11%
Net Income, GAAP
132.7%
184.66%
719.59%
Sales/Revenue/Turnover
- -
53.81%
12.13%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
104
116
114
126
460
2022
124
137
134
122
516
2023
117
121
121
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.56
0.66
-0.91
-0.9
-1.8
2022
-0.8
-10.87
-1.27
-0.41
-13.18
2023
-0.77
-0.78
-3.42
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Puriblood Medical Co., Ltd. (6847.TWO)
Vijaya Diagnostic Centre Limited (VIJAYA.NS)
Chemclin Diagnostics Co., Ltd. (688468.SS)
NovelStem International Corp. (NSTM)
Pangaea Oncology, S.A. (PANG.MC)
Hangzhou Tigermed Consulting Co., Ltd. (3347.HK)
Business
Invitae Corporation (NVTAQ), a medical genetics company, provides genetic testing services utilizing next-generation sequencing and bioinformatics to deliver actionable insights for hereditary conditions, including comprehensive panels and exome sequencing for oncology, such as breast, ovarian, colon and prostate cancers; cardiology, covering hypertrophic cardiomyopathy and long QT syndrome; neurology, including epilepsy and movement disorders; pediatrics; rare and undiagnosed diseases like metabolic disorders; carrier screening; and other hereditary conditions such as preimplantation and pathology diagnostics. The company offers these services to patients, healthcare providers, biopharma companies and pharmaceutical partners, with operations primarily in the United States and support extended to Canada through genetic counseling included at no additional cost for eligible tests. Founded in 2010 and headquartered in San Francisco, California, Invitae serves diverse customer types across these therapeutic segments via flexible billing options and integration with clinical practices. In August 2024, Labcorp finalized its acquisition of select Invitae assets, integrating the company's genetic testing technology focused on oncology and select rare diseases into Labcorp's specialty testing capabilities to enhance offerings from therapy development through diagnosis and personalized treatment. This transaction followed Invitae's Chapter 11 bankruptcy filing in February 2024, which transitioned to a liquidation plan approved in August 2024, enabling continuity for customers amid prior divestitures of assets like Ciitizen to address accumulated debt from 13 acquisitions between 2019 and 2021. Through this Labcorp partnership, Invitae advances genetic data utilization for clinical trials, patient care and health outcomes, leveraging nationwide patient service centers and coverage by most health plans.

Company News

APIChat

  • prnewswire.com

    Labcorp Finalizes Acquisition of Select Assets of Invitae

  • prnewswire.com

    Invitae Launches Unlock™ Behind the Seizure® Program for Pediatric Epilepsy Patients